Analysts Offer Insights on Healthcare Companies: Albireo Pharma Inc (NASDAQ: ALBO), Adverum Biotechnologies (NASDAQ: ADVM) and Incyte Corp (NASDAQ: INCY)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma Inc (ALBOResearch Report), Adverum Biotechnologies (ADVMResearch Report) and Incyte Corp (INCYResearch Report) with bullish sentiments.

Albireo Pharma Inc (ALBO)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Albireo Pharma Inc on April 15. The company’s shares closed yesterday at $32.98.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 28.9% and a 54.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma Inc with a $60.33 average price target, which is an 82.9% upside from current levels. In a report issued on April 10, Needham also maintained a Buy rating on the stock with a $50 price target.

See today’s analyst top recommended stocks >>

Adverum Biotechnologies (ADVM)

In a report issued on April 15, Phil Nadeau from Cowen & Co. maintained a Buy rating on Adverum Biotechnologies. The company’s shares closed yesterday at $5.94.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 10.2% and a 51.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adverum Biotechnologies with a $8 average price target, implying a 34.7% upside from current levels. In a report issued on April 15, Piper Jaffray also maintained a Buy rating on the stock with a $8 price target.

Incyte Corp (INCY)

In a report issued on April 12, Marc Frahm from Cowen & Co. reiterated a Buy rating on Incyte Corp. The company’s shares closed yesterday at $76.98.

According to TipRanks.com, Frahm is a 3-star analyst with an average return of 5.1% and a 61.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Unum Therapeutics Inc.

Incyte Corp has an analyst consensus of Moderate Buy, with a price target consensus of $90.90, a 18.1% upside from current levels. In a report issued on April 12, Barclays also maintained a Buy rating on the stock with a $90 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.